What changed: Localised penile cancer (organ-confined, node-negative)
Every dated change on the records linked to Localised penile cancer (organ-confined, node-negative), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2023 · 5
- 2023GuidelineLocalised penile cancer (organ-confined, node-negative)Guideline EAU-ASCO Collaborative Guideline on Penile Cancer 2023: Clinically negative groins
Surveillance for low-risk tumours (Ta, T1 grade 1 without lymphovascular invasion); dynamic sentinel node biopsy for intermediate- and high-risk tumours, with inguinal lymphadenectomy if positive.
- 2023GuidelineLocalised penile cancer (organ-confined, node-negative)Guideline EAU-ASCO Collaborative Guideline on Penile Cancer 2023: Penile intraepithelial neoplasia
Circumcision if the foreskin is involved; topical fluorouracil or imiquimod, laser ablation or glans resurfacing; close follow-up because recurrence is common.
- 2023GuidelineLocalised penile cancer (organ-confined, node-negative)Guideline EAU-ASCO Collaborative Guideline on Penile Cancer 2023: Prevention
HPV vaccination (now offered to boys in many countries and being tested in Chinese men) and treatment of phimosis and lichen sclerosus.
- 2023GuidelineLocalised penile cancer (organ-confined, node-negative)Guideline EAU-ASCO Collaborative Guideline on Penile Cancer 2023: T1 to T2 tumours
Organ-sparing surgery (wide local excision, glansectomy, partial penectomy) with narrow margins; brachytherapy for small distal tumours; total penectomy only for large or proximal disease.
- 2023MilestoneSentinel lymph node biopsyEAU-ASCO collaborative guideline sets organ preservation and sentinel node biopsy as standards
A milestone in how this cancer is treated.